ArticleScientific reports2025
Ulinastatin modulates TRPM4 expression and apoptosis to mitigate cognitive dysfunction in aged perioperative neurocognitive disorder rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Perioperative neurocognitive disorder (PND) is a long-term perioperative complication that affects elderly surgical patients. As the aging population continues to grow, the prevention and treatment of PND have become important issues to address. Research has shown that ulinastatin significantly reduces the incidence of PND in elderly patients undergoing various types of surgery, including spinal and abdominal surgeries. However, the underlying mechanisms of this effect remain unclear. Transient receptor potential melastatin 4 (TRPM4) is a Ca2 + -activated, monovalent cation channel associated with many neurological diseases. In the present study, we aimed to investigate the relationship between ulinastatin and TRPM4 in PND and to determine its underlying mechanism. Forty eighteen-month-old male Sprague‒Dawley rats were randomly divided into four groups: the sham group, surgery group (internal fixation of tibial fracture), ulinastatin group (ulinastatin + surgery), and 9-phenanthrol group (TRPM4 channel inhibitor 9-phenanthrol + surgery). The neurocognitive function of the rats was detected using the Y-maze and new object recognition (NOR) tests. We used WB, qPCR, and IF to detect the expression levels of TRPM4 in different groups of rats. We also detected the degree of apoptosis in rat hippocampal cells. Surgery under inhaled sevoflurane anesthesia induced cognitive impairments and elevated the expression of TRPM4 in the hippocampus. Downregulation of TRPM4 expression by ulinastatin or 9-phenanthrol alleviated cognitive impairments after anesthesia and surgery. Furthermore, ulinastatin treatment decreased the level of apoptosis in the hippocampus. Ulinastatin downregulates TRPM4 expression and apoptosis to mitigate cognitive dysfunction in aged perioperative neurocognitive disorder rats, and ulinastatin is a promising neuroprotectant against PND.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.